168 related articles for article (PubMed ID: 8413948)
1. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Uitti RJ; Ahlskog JE; Maraganore DM; Muenter MD; Atkinson EJ; Cha RH; O'Brien PC
Neurology; 1993 Oct; 43(10):1918-26. PubMed ID: 8413948
[TBL] [Abstract][Full Text] [Related]
2. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
Scigliano G; Musicco M; Soliveri P; Piccolo I; Girotti F; Giovannini P; Caraceni T
Neurology; 1990 Feb; 40(2):265-9. PubMed ID: 2300246
[TBL] [Abstract][Full Text] [Related]
3. Clinical course of patients with idiopathic Parkinson's disease.
Roos RA; Jongen JC; van der Velde EA
Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
[TBL] [Abstract][Full Text] [Related]
4. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
5. [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
Datieva VK; Makotrova TA; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):13-9. PubMed ID: 23250605
[TBL] [Abstract][Full Text] [Related]
6. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
[TBL] [Abstract][Full Text] [Related]
7. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
8. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.
Hely MA; Morris JG; Traficante R; Reid WG; O'Sullivan DJ; Williamson PM
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):300-7. PubMed ID: 10449550
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease patients first treated at age 75 years or older: a comparative study.
Peretz C; Chillag-Talmor O; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Giladi N
Parkinsonism Relat Disord; 2014 Jan; 20(1):69-74. PubMed ID: 24183677
[TBL] [Abstract][Full Text] [Related]
10. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
12. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
Sweet RD; McDowell FH
Ann Intern Med; 1975 Oct; 83(4):456-63. PubMed ID: 1166978
[TBL] [Abstract][Full Text] [Related]
13. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
14. Parkinsonism treated with levodopa: progression and mortality.
Maier Hoehn MM
J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
[TBL] [Abstract][Full Text] [Related]
15. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
17. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
19. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
20. Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
Rahman MM; Uddin MJ; Chowdhury JH; Chowdhury TI
Mymensingh Med J; 2014 Jan; 23(1):18-23. PubMed ID: 24584367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
